SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing strong bullish momentum, underpinned by a fresh analyst upgrade citing robust hyperscaler demand for its server CPUs and significant progress in advanced manufacturing yields. The community is buzzing with optimism about Intel's turnaround, anticipating substantial growth as a leading chip foundry and discussing potential major customer wins and government support. Many believe shorts are trapped, expecting continued upward movement.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending amidst community concern over its CEO's consistent, pre-planned share sales and apprehension regarding new AI agents like Anthropic's Claude. Despite some immediate 'panic selling,' many investors view the resulting price dip as an 'easy buy' opportunity, emphasizing UiPath's strong enterprise presence, robust financials, and leadership in 'agentic AI' as a competitive moat.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe (ADBE) is currently experiencing significant downward pressure following multiple analyst downgrades and concerns over intensifying AI competition from emerging tools and rival offerings, despite reporting better-than-expected earnings. The community is sharply divided, with many perceiving it as an "AI victim" and "value trap," while a bullish contingent highlights its robust fundamentals, strong cash flow, and market leadership as an "undervalued steal" amidst the broader software sector's struggles.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending due to its continued strategy of accumulating significant Bitcoin holdings, which has sparked renewed optimism among investors. Community discussions highlight strong bullish sentiment and the potential for a short squeeze, although some express concern about the impact of the company's equity offerings. Ultimately, many believe MSTR's performance remains highly correlated with Bitcoin's sustained upward trajectory.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is a top trending stock due to intense community excitement around its extremely low share float, massive short interest, and high cost to borrow, all fueling widespread speculation of an imminent short squeeze. Traders are closely watching for a breakout, with recent long-term healthcare contracts and upcoming earnings announcements seen as potential catalysts that could mirror explosive moves in similar low-float securities.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with strong community buzz fueled by its upcoming J.P. Morgan Healthcare Conference presentation and a recent analyst upgrade. Investors are keenly anticipating announcements regarding new partnerships and broader applications for its Matrix-M platform, especially in oncology. High short interest further ignites speculation of a potential squeeze, as recent filings signal strategic business updates aimed at de-risking the company.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

AHMA is experiencing significant price volatility and high trading volume, primarily driven by community speculation surrounding its extremely low share float as a recent IPO. Many investors are actively discussing the potential for a substantial short squeeze, often drawing comparisons to other recent low-float runners. This dynamic is fueling aggressive buying and ambitious price targets among traders.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is seeing intense market conversation after reporting substantial revenue expansion, positioning it as a key player in the defense drone industry. The community is buzzing with anticipation over its "Blue UAS" technology, including the Black Widow and FANG drones, with discussions centered on potential major contract awards from programs like the Drone Dominance initiative. This excitement is further fueled by increased defense sector spending and speculation around its significant short interest.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending amidst widespread community speculation about an imminent major partnership or acquisition, notably with Big Pharma firms, fueled by recent FDA flexibility regarding CMC requirements and upcoming industry conferences. Investors are keenly anticipating a substantial buyout and a potential short squeeze, given the promising Phase 3 data for its lead prostate cancer drug and upcoming Biologics License Application submission in 2026. This fervent discussion occurs within a broader market context of accelerated biopharma M&A activity driven by looming patent cliffs.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending after the FDA extended the PDUFA review timeline for its FSGS drug, FILSPARI, to April 13, 2026, classifying the company's responses to information requests as a "Major Amendment." While this news led to a significant share price drop, the community is deeply divided on its implications. Investors are actively debating whether this extension, without safety concerns, increases the likelihood of eventual approval by allowing further data characterization, or if it signals prolonged uncertainty for the rare kidney disease treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Bolt Biotherapeutics Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$6.16
Prev Close	$5.81
Open	$5.97
Dividend Yield	0.00%
50-Day Moving Average	$5.25
Beta	0.94
Avg. Volume	57,764.91
PE Ratio	-0.26

52-Week High	$11.70
52-Week Low	$4.41
Market Capitalization	$11.15M
EPS (Annual)	-$33.06
Price to Book	0.35
Revenue Per Employee	$147,884.61
Enterprise Value/EBITDA	N/A

BOLT
Bolt Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BOLT News

BOLTBolt Biotherapeutics Inc